184 related articles for article (PubMed ID: 24947791)
1. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
Henry RR; Mudaliar S; Ciaraldi TP; Armstrong DA; Burke P; Pettus J; Garhyan P; Choi SL; Jacober SJ; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen N; Sinha VP; Linnebjerg H
Diabetes Care; 2014 Sep; 37(9):2609-15. PubMed ID: 24947791
[TBL] [Abstract][Full Text] [Related]
2. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
Mudaliar S; Henry RR; Ciaraldi TP; Armstrong DA; Burke PM; Pettus JH; Garhyan P; Choi SL; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen NK; Sinha VP; Linnebjerg H; Jacober SJ
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():17-24. PubMed ID: 27723226
[TBL] [Abstract][Full Text] [Related]
3. Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial.
Morrow LA; Hompesch M; Jacober SJ; Leng Choi S; Qu Y; Sinha VP
Diabetes Obes Metab; 2016 Nov; 18(11):1065-1071. PubMed ID: 27169522
[TBL] [Abstract][Full Text] [Related]
4. Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Porksen N; Linnebjerg H; Garhyan P; Lam EC; Knadler MP; Jacober SJ; Hoevelmann U; Plum-Moerschel L; Watkins E; Gastaldelli A; Heise T
Diabetes Obes Metab; 2017 Apr; 19(4):482-488. PubMed ID: 27888561
[TBL] [Abstract][Full Text] [Related]
5. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
[TBL] [Abstract][Full Text] [Related]
6. Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion.
Tiffner K; Boulgaropoulos B; Höfferer C; Birngruber T; Porksen N; Linnebjerg H; Garhyan P; Lam ECQ; Knadler MP; Pieber TR; Sinner F
Diabetes Technol Ther; 2017 May; 19(5):305-314. PubMed ID: 28328234
[TBL] [Abstract][Full Text] [Related]
7. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
8. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
Ginsberg H; Cariou B; Orchard T; Chen L; Luo J; Bastyr EJ; Bue-Valleskey J; Chang AM; Ivanyi T; Jacober SJ; Hoogwerf BJ
Diabetes Obes Metab; 2016 Nov; 18(11):1089-1092. PubMed ID: 27486125
[TBL] [Abstract][Full Text] [Related]
9. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles.
Mudaliar S; Mohideen P; Deutsch R; Ciaraldi TP; Armstrong D; Kim B; Sha X; Henry RR
Diabetes Care; 2002 Sep; 25(9):1597-602. PubMed ID: 12196433
[TBL] [Abstract][Full Text] [Related]
10. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes.
Johansen RF; Søndergaard E; Linnebjerg H; Garhyan P; Lam ECQ; Porksen N; Jacober SJ; Nielsen S
Diabetes Obes Metab; 2018 Feb; 20(2):419-426. PubMed ID: 28817248
[TBL] [Abstract][Full Text] [Related]
11. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus.
Porksen NK; Linnebjerg H; Lam ECQ; Garhyan P; Pachori A; Pratley RE; Smith SR
Diabetes Obes Metab; 2018 May; 20(5):1193-1201. PubMed ID: 29316143
[TBL] [Abstract][Full Text] [Related]
12. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
14. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.
Blevins T; Pieber TR; Colón Vega G; Zhang S; Bastyr EJ; Chang AM;
Diabetes Obes Metab; 2016 Nov; 18(11):1072-1080. PubMed ID: 27234693
[TBL] [Abstract][Full Text] [Related]
15. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
[TBL] [Abstract][Full Text] [Related]
16. Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
Rosenstock J; Marre M; Qu Y; Zhang S; Bastyr EJ; Prince MJ; Chang AM
Diabetes Obes Metab; 2016 Nov; 18(11):1093-1097. PubMed ID: 27484021
[TBL] [Abstract][Full Text] [Related]
17. Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.
Jacober SJ; Prince MJ; Beals JM; Hartman ML; Qu Y; Linnebjerg H; Garhyan P; Haupt A
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():3-16. PubMed ID: 27723228
[TBL] [Abstract][Full Text] [Related]
18. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
Cusi K; Sanyal AJ; Zhang S; Hoogwerf BJ; Chang AM; Jacober SJ; Bue-Valleskey JM; Higdon AN; Bastyr EJ; Haupt A; Hartman ML
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():50-58. PubMed ID: 27723227
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1.
Garg S; Dreyer M; Jinnouchi H; Mou J; Qu Y; Hartman ML; Rosilio M; Jacober SJ; Bastyr EJ;
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():25-33. PubMed ID: 27393697
[TBL] [Abstract][Full Text] [Related]
20. Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro in type 1 diabetes: IMAGINE 7 study.
Garg S; Selam JL; Bhargava A; Schloot N; Luo J; Zhang Q; Jacobson JG; Hoogwerf BJ
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():43-49. PubMed ID: 27393722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
